The global tadalafil market is expected to rise at a considerable CAGR during the forecast period (2022-2028). The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launch, and product innovation to remain competitive in the marketplace. For instance, in March 2019, Dr. Reddy’s Laboratories announced the launch of tadalafil tablets in the US market. The authorised product is a therapeutically equivalent generic form of Cialis (tadalafil) tablets. Dr. Reddy's Tadalafil pills are available in four strengths: 2.5 mg, 5 mg, 10 mg, and 20 mg, each in a 30-count container size. Further, in February 2019, Cipla's Abbreviated New Drug Application (ANDA) for Tadalafil Tablets 20mg received final approval from the US Food and Drug Administration (US FDA). Cipla's Tadalafil Tablets 20mg are an AB-rated generic drug similar to Eli Lilly and Co.'s Adcirca. It's a phosphodiesterase 5 (PDE5) inhibitor intended to help persons with pulmonary arterial hypertension (PAH) exercise more effectively (WHO Group 1).
Browse the full report description of “Global Tadalafil Market Size, Share and Trends Analysis Report by Type (Purity: 98% and Purity: above 98%), by Application (Erectile Dysfunction, Benign Prostatic Hyperplasia, and Others) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/tadalafil-market
Besides, in March 2019, after getting final approval from the US FDA to market the medication in the strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg, Zydus Cadila announced the Day 1 launch of Tadalafil Tablets USP (US RLD Cialis Tablets). The drug, is manufactured at the group's plant in Moraiya, Ahmedabad, and is used to treat erectile dysfunction (impotence) and the symptoms of benign prostatic hypertrophy (enlarged prostate).
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Type
o By Application
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
1.1. Competitive Landscape- Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Eli Lilly and Co. Pvt. Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., and others.
Key questions addressed by the report
• What is the market growth rate?
• That segment and region dominate the market in the base year?
• That segment and region will project the fastest growth in the market?
• How does COVID-19 impact the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Tadalafil Market Report by Segment
By Type
By Application
Global Tadalafil Market Report Segment by Region
North America
• US
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East and Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/tadalafil-market